Sibel BULGURCUOĞLU KURAN, Emine Hande KARAGEDİK, Cem İYİBOZKURT, Elif Sinem İPLİK, BEDİA ÇAKMAKOĞLU, Arzu ERGEN

Prevalence of MMP-3 E45K polymorphism in Turkish patients with endometrial carcinoma

Endometrial carcinoma is a metastatic and recurrent disease has a worse prognosis. We aim to investigate the MMP-3 gene polymorphism in Turkish patients with endometrial carcinoma. In recent years, number of genetic studies have been increased to find new prognostic and theraupeutic markers. Matrix metalloproteinases [MMPs] are proteolytic enzymes that degrade all components of the extracellular matrix which are play an important role of cancer metastasis and invasion. MMP-3, also known as stromelysin-1, to lyse basal membrane collagen and induce the synthesis of some other MMPs. 97 patients with endometrial carcinoma and 100 healthy controls were included in this study. MMP-3 E45K polymorphism was determined using polymerase chain reaction/ restriction fragment length polymorphism in study groups. There were no significant differences between any genotypes or allele in control and patient groups for MMP-3 E45K polymorphism. Besides no significant correlation was found between MMP-3 E45K polymorphisms and clinical characteristics, such as histology, grade, metastasis and family history. ur study suggests that the MMP-3 E45K polymorphism is not associated with endometrial carcinoma process in Turkish patients.

PDF

___

Colombo N, Preti E, Landoni F, et al. ESMO Guidelines Working Group. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22:35-9.

Nicholson MR, Iyengar P, Hummer AJ, et al. Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. Modern Pathol. 2009;19:1091-100.

Noguera R, Nieto OA, Tadeo I, et al. Extracellular matrix, biotensegrity and tumor microenvironment. An update and overview. Histol Histopathol. 2012;27:693-705.

Rozario T, DeSimone DW. The extracellular matrix in development and morphogenesis: A dynamic view. Dev Biol. 2010;341:126-40.

Catalano V, Turdo A, Di F, et al. Tumor and its microenvironment: A synergistic interplay. Semin Cancer Biol. 2013;23:522-32.

Lu P, Weaver VM, Werb ZJ. The extracellular matrix: A dynamic niche in cancer progression. J Cell Biol. 2012;20:395-406.

Deryugina E, Quigley J. Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: contrasting, overlapping and compensatory functions. Biochim Biophys Acta. 2010;1803:103-20.

Butler GS, Overall CM. Updated biological roles for matrix metalloproteinases and new “intracellular” substrates revealed by degradomics. Biochemistry. 2009;48:10830-45.

Honkavuori M, Talvensaari-Mattila A, Soini Y,et al. 2007. MMP-2 expression associates with CA 125 and clinical course in endometrial carcinoma. Gynecol Oncol. 104:217-21.

Brinckerhoff CE, Rutter JL, Benbow U. Interstitial collagenases as markers of tumor progression. Clinical cancer research: an official journal of the American Association for Cancer Research. 2000;6:4823-30.

Bodey B, Bodey B Jr, Siegel SE, et al. Matrix metalloproteinase expression in childhood astrocytomas. Anticancer Res. 2000;20:3287-92.

Mercapide J, Lopez De Cicco R, Castresana JS, et al. Stromelysin-1/matrix metalloproteinase-3 (MMP-3) expression accounts for invasive properties of human astrocytoma cell lines. Int J Cancer. 2003;106:676–82.

Blons H, Gad S, Zinzindohoue F, et al. Matrix metalloproteinase 3 polymorphism: a predictive factor of response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma. Clin Cancer Res. 2004;10:25949.

Szyllo K, Smolarz B, Romanowicz-Makowska H, et al. The promoter polymorphism of the matrix metalloproteinase 3 (MMP-3) gene in women with ovarian cancer. J Exp Clin Cancer Res. 2002;21:357-61.

Raleigh SM, van der Merwe L, Ribbans WJ, et al. Variants within the MMP3 gene are associated with Achilles tendinopathy: possible interaction with the COL5A1 gene. Br J Sports Med. 2009;43:514-20. 1

Ricketts C, Zeegers MP, Lubinski J, et al. Analysis of germline variants in CDH1, IGFBP3, MMP1, MMP3, STK15 and VEGF in familial and sporadic renal cell carcinoma. PLoS One. 2009;4:e6037.

Beeghly-Fadiel A, Xiang YB, Deming SL, et al. No association between matrix metalloproteinase (MMP)-1, MMP-3, and MMP-7 SNPs and endometrial cancer risk. Cancer Epidemiol Biomarkers Prev. 2009;18:19258.

Nan H, Niu T, Hunter DJ, et al. Missense polymorphisms in matrix metalloproteinase genes and skin cancer risk. Cancer Epidemiol Biomarkers Prev. 2008;17:3551-7.

Miller SA, Dykes, DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.

Guan X, Wang X, Luo H, et al. Matrix metalloproteinase 1, 3, and 9 polymorphisms and esophageal squamous cell carcinoma risk. Med Sci Monit. 2014;20:2269-74.

Shevchenko AV, Konenkov VI, Garbukov EIu, et al. Associating ofpolymorphism in the promoter regions of genes of metalloproteinase (MMP2, MMP3,MMP9) with options of the clinical course of breast cancer in Russian women. Vopr Onkol. 2014;60:630-5.

Motovali-Bashi M, Hojati Z, Hajihoseiny S, et al. The stromelysin-1 5A/5A genotype enhances colorectal cancer cell invasion in Iranian population. J Res Med Sci. 2012;17:962-6.

Ling Y, Peng C, Liu C, et al. Gene polymorphism of IL-6 and MMP-3 decreases passive range of motion after rotator cuff repair. Int J Clin Exp Pathol. 2015;5:5709–14.

Ma AJ, Fan LY, Li WJ, et al. Association of matrix metalloproteinase-3 gene polymorphisms with subtypes of ischemic stroke. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2013;30:461-6. Mannelqvist M, Stefansson IM, Bredholt G, et al. Gene expression patterns related to vascular invasion and aggressive features in endometrial cancer. Am J Pathol. 2011;178:861-71.